A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
Completed
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Drug: Safety observation
- Registration Number
- NCT00148369
- Lead Sponsor
- Amgen
- Brief Summary
The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson's disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- Subjects must have a diagnosis of bilateral, idiopathic Parkinson's Disease who have been enrolled and treated with intraputaminal infusion of liatermin in a previous Amgen/Medtronic-sponsored trial (protocols 20010109 or 20030160) or the Bristol open-label study - At time of implant (Study 20030168), subjects need to have been 35 to 70 years of age
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Observational Group Safety observation Subjects previously administered GDNF and have discontinued the drug.
- Primary Outcome Measures
Name Time Method Adverse Events 24 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the long-term effects of intraputaminal r-metHuGDNF infusion in Parkinson's disease patients?
How does GDNF therapy compare to standard-of-care treatments for idiopathic Parkinson's disease?
What biomarkers correlate with antibody development against r-metHuGDNF in Parkinson's patients?
What adverse events are associated with GDNF infusion in Parkinson's disease registries?
Are there combination therapies involving GDNF for Parkinson's disease under investigation?